SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-162881
Filing Date
2021-05-17
Accepted
2021-05-17 08:35:03
Documents
14
Period of Report
2021-05-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d177170d8k.htm   iXBRL 8-K 26434
2 EX-99.1 d177170dex991.htm EX-99.1 52352
6 GRAPHIC g177170g0517165831338.jpg GRAPHIC 3756
  Complete submission text file 0001193125-21-162881.txt   217636

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fstx-20210517.xsd EX-101.SCH 3078
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fstx-20210517_lab.xml EX-101.LAB 18054
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fstx-20210517_pre.xml EX-101.PRE 11386
7 EXTRACTED XBRL INSTANCE DOCUMENT d177170d8k_htm.xml XML 3348
Mailing Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT
Business Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT 44 1223 497400
F-star Therapeutics, Inc. (Filer) CIK: 0001566373 (see all company filings)

IRS No.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37718 | Film No.: 21927783
SIC: 2834 Pharmaceutical Preparations